Natera Beats on 34% Revenue Growth, Lifts 2026 Guidance by $140M
NTRA has more than doubled off its 52-week low of $181 on elevated volume (1.9× avg).
Summary
Natera posted Q3 2026 revenue of $794.0 million, up 34.1% from $592.2 million a year ago, and raised full-year 2026 revenue guidance by $140 million at the midpoint to $3.005-$3.035 billion. Oncology test volume did the heavy lifting: roughly 339,500 tests processed, up 60.9%, with clinical MRD units adding 32,700 sequentially. Gross margin held at 64.7%, and the net loss narrowed to $59.9 million, or $0.42 per share, from $87.5 million a year earlier. Cash rose about $5.7 million sequentially to $1.097 billion, and management guided to positive cash flow for the year. The guidance raise is the number that matters — it implies the reimbursement wins, including the recent CMS MolDX coverage for serial Signatera testing in hepatocellular carcinoma, are converting into revenue faster than the Street modeled. Watch the 4:30 p.m. ET call for detail on the size of the true-up benefit and oncology ASP trends.
At the time of this announcement, NTRA was trading at $363.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.4B. The 52-week trading range was $181.00 to $437.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.